[{"orgOrder":0,"company":"Gates Biomanufacturing Facility","sponsor":"Institute for Molecular Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV-1980R","moa":"Tau aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Gates Biomanufacturing Facility","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gates Biomanufacturing Facility \/ Institute for Molecular Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Gates Biomanufacturing Facility \/ Institute for Molecular Medicine"}]

Find Clinical Drug Pipeline Developments & Deals by Gates Biomanufacturing Facility

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          APGA Annual Conference
                          Not Confirmed
                          APGA Annual Conference
                          Not Confirmed

                          Details : AV-1980R, an anti-Tau recombinant protein vaccines targets Alzheimer's Disease and other Tau aggregation-associated neurodegenerative conditions by providing outstanding levels of antibody protection against harmful forms of Tau protein that may lead to ...

                          Product Name : AV-1980R

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 11, 2022

                          Lead Product(s) : AV-1980R

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Institute for Molecular Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank